[Treatment of conjunctival intraepithelial neoplasia with topical mitomycin C 0.02%].
To evaluate the efficacy of topical mitomycin C (MMC) 0.02% in treating conjunctival intraepithelial neoplasia (CIN). Three patients with CIN were treated with topical MMC 0.02%. Our follow-up period was twelve months (range 8-18 months). CIN was resolved in all three cases without modifying the normal corneal and conjunctival architecture. Topical MMC 0.02% four times daily during two weeks is a useful alternative tool for the surgical management of CIN.